コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 classified with 5 categories from the Joint National Committee 7 with a sixth category added to dist
2 using the microdilution format assay of the National Committee for Clinical Laboratory Standards (NC
4 treonam as resistant as suggested by current National Committee for Clinical Laboratory Standards (NC
5 s by a microdilution method adopted from the National Committee for Clinical Laboratory Standards (NC
6 and broth) and procedures recommended by the National Committee for Clinical Laboratory Standards (NC
7 ken to determine the accuracy of the current National Committee for Clinical Laboratory Standards (NC
8 402 yeast isolates was assessed against the National Committee for Clinical Laboratory Standards (NC
9 ollowing a procedure under evaluation by the National Committee for Clinical Laboratory Standards (NC
10 SabDex) with fluconazole was compared to the National Committee for Clinical Laboratory Standards (NC
11 se (YNB) broth microdilution method with the National Committee for Clinical Laboratory Standards (NC
12 rding to a procedure under evaluation by the National Committee for Clinical Laboratory Standards (NC
13 lysed horse blood, similar in concept to the National Committee for Clinical Laboratory Standards (NC
14 ared in four different laboratories with the National Committee for Clinical Laboratory Standards (NC
15 antifungal susceptibility testing using the National Committee for Clinical Laboratory Standards (NC
16 tance according to current guidelines of the National Committee for Clinical Laboratory Standards (NC
18 ermediate, or resistant according to current National Committee for Clinical Laboratory Standards (NC
19 ndida with fluconazole was compared with the National Committee for Clinical Laboratory Standards (NC
20 x separate laboratories tested replicates of National Committee for Clinical Laboratory Standards (NC
21 istant strains were determined by use of the National Committee for Clinical Laboratory Standards (NC
22 d was equivalent to phenotypic DST using the National Committee for Clinical Laboratory Standards (NC
24 in B and fluconazole susceptibilities by the National Committee for Clinical Laboratory Standards (NC
25 red in three different laboratories with the National Committee for Clinical Laboratory Standards (NC
27 ida spp. was assessed in comparison with the National Committee for Clinical Laboratory Standards (NC
28 voriconazole were compared with that of the National Committee for Clinical Laboratory Standards (NC
29 lus spp. was assessed in comparison with the National Committee for Clinical Laboratory Standards (NC
30 tococcus neoformans was assessed against the National Committee for Clinical Laboratory Standards (NC
31 e selected 131 E. coli isolates that met the National Committee for Clinical Laboratory Standards (NC
32 d according to procedures established by the National Committee for Clinical Laboratory Standards (NC
33 veterinary methods recently developed by the National Committee for Clinical Laboratory Standards (NC
34 ates) to nine antimicrobial agents using the National Committee for Clinical Laboratory Standards (NC
35 tes of Candida spp. was assessed against the National Committee for Clinical Laboratory Standards (NC
37 tes of Candida spp. was assessed against the National Committee for Clinical Laboratory Standards (NC
39 andida spp. was assessed against that of the National Committee for Clinical Laboratory Standards (NC
40 ested by broth microdilution against various National Committee for Clinical Laboratory Standards (NC
41 ared with visual determination of MIC by the National Committee for Clinical Laboratory Standards (NC
42 eloped by the Antifungal Subcommittee of the National Committee for Clinical Laboratory Standards (NC
43 us fungi was assessed in comparison with the National Committee for Clinical Laboratory Standards (NC
45 ents against the results generated using the National Committee for Clinical Laboratory Standards (NC
46 nd by six independent laboratories using the National Committee for Clinical Laboratory Standards (NC
47 icrodilution test performed according to the National Committee for Clinical Laboratory Standards (NC
49 conducted according to the guidelines of the National Committee for Clinical Laboratory Standards and
50 by the standard broth macrodilution method (National Committee for Clinical Laboratory Standards app
51 more appropriate breakpoint than the current National Committee for Clinical Laboratory Standards bre
52 " of growth during susceptibility testing by National Committee for Clinical Laboratory Standards bro
53 ole, and ravuconazole were determined by the National Committee for Clinical Laboratory Standards bro
55 performed according to the guidelines of the National Committee for Clinical Laboratory Standards by
56 SBL)-producing isolates testing resistant by National Committee for Clinical Laboratory Standards cri
57 MB agar plates were prepared as described in National Committee for Clinical Laboratory Standards doc
59 y according to procedures established by the National Committee for Clinical Laboratory Standards for
60 e and gram-negative strains that fulfill the National Committee for Clinical Laboratory Standards gui
61 m/ml susceptible category defined by current National Committee for Clinical Laboratory Standards gui
62 termined for 10 clinical isolates, following National Committee for Clinical Laboratory Standards gui
63 elated well with the results obtained by the National Committee for Clinical Laboratory Standards M27
64 igational triazole voriconazole by using the National Committee for Clinical Laboratory Standards M27
65 bility testing method, the recently released National Committee for Clinical Laboratory Standards M27
66 B were tested by using a modification of the National Committee for Clinical Laboratory Standards M27
67 TCC 6258) were tested in accordance with the National Committee for Clinical Laboratory Standards M27
68 rent sites and compared this method with the National Committee for Clinical Laboratory Standards M27
70 Testing was performed in accordance with the National Committee for Clinical Laboratory Standards M27
72 olved upon repeat testing were tested by the National Committee for Clinical Laboratory Standards M7-
73 Antifungal susceptibility testing using the National Committee for Clinical Laboratory Standards mac
74 concentrations (MICs) were determined by the National Committee for Clinical Laboratory Standards met
75 ic susceptibilities of P. acnes by using the National Committee for Clinical Laboratory Standards met
76 e detection of mecA by PCR with detection by National Committee for Clinical Laboratory Standards met
77 ricin B, and 5-fluorocytosine (5FC) by using National Committee for Clinical Laboratory Standards mic
78 f fluconazole was determined by the standard National Committee for Clinical Laboratory Standards pro
79 ility testing method with the results of the National Committee for Clinical Laboratory Standards ref
81 ere compared to the results generated by the National Committee for Clinical Laboratory Standards ref
83 erence macrodilution method developed by the National Committee for Clinical Laboratory Standards Sub
84 sistance according to the definitions of the National Committee for Clinical Laboratory Standards wer
85 the M. marinum strains tested (MIC90, at the National Committee for Clinical Laboratory Standards) br
86 boratory Standards Institute (CLSI; formerly National Committee for Clinical Laboratory Standards) br
87 tive criteria and QC limits (accepted by the National Committee for Clinical Laboratory Standards) sh
88 Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards).
89 Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards).
90 By using the interpretive guidelines of the National Committee for Clinical Laboratory Standards, 26
91 susceptibility has been standardized by the National Committee for Clinical Laboratory Standards, an
92 boratory Standards Institute (CLSI; formerly National Committee for Clinical Laboratory Standards, or
93 rmed according to the recommendations of the National Committee for Clinical Laboratory Standards, wa
94 ults compared to the time to availability of National Committee for Clinical Laboratory Standards-rec
95 ed by the standard method recommended by the National Committee for Clinical Laboratory Standards.
96 st value within the range recommended by the National Committee for Clinical Laboratory Standards.
97 tentative broth macrodilution method of the National Committee for Clinical Laboratory Standards.
98 and microdilution methods recommended by the National Committee for Clinical Laboratory Standards.
99 was determined by methods recommended by the National Committee for Clinical Laboratory Standards.
100 by the reference agar dilution method of the National Committee for Clinical Laboratory Standards.
101 microdilution method, as recommended by the National Committee for Clinical Laboratory Standards.
102 ntial advantages over the M27-A assay of the National Committee for Clinical Laboratory Standards.
103 is study is recommended for inclusion in the National Committee for Laboratory Standards method for t
106 health insurance plans participating in the National Committee for Quality Assurance (NCQA) quality
108 s) participating in the HEDIS program of the National Committee for Quality Assurance during 1999, an
109 ns that reported quality-of-care data to the National Committee for Quality Assurance for 2002 and 20
110 st (level 3) medical-home recognition by the National Committee for Quality Assurance, a designation
111 atients cared for by providers practicing in National Committee for Quality Assurance-recognized pati
112 atients cared for by providers practicing in National Committee for Quality Assurance-recognized pati
116 panel members appointed to the Eighth Joint National Committee (JNC 8)" disqualified nearly 98% of p
117 panel members appointed to the Eighth Joint National Committee (JNC 8)" has generated considerable c
118 panel members appointed to the Eighth Joint National Committee (JNC 8; 2014 BP guideline) proposed l
119 published in the Seventh Report of the Joint National Committee (JNC) on Prevention, Detection, Evalu
120 Since 2003, the Seventh Report of the Joint National Committee (JNC-7) has been the predominant guid
121 eatment at visit 2 based on the Eighth Joint National Committee (JNC-8) hypertension guidelines const
123 tudy was to examine the association of Joint National Committee (JNC-V) blood pressure and National C
125 lationships to the sixth report of the Joint National Committee (JNC-VI) on Prevention, Detection Eva
126 cted in agreement with the guidelines of the National Committee of Ethic Reflection on Animal Experim
128 eatment and management guidelines, the Joint National Committee on Detection, Evaluation, and Treatme
129 are preparing the Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation
130 uideline and the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,
131 criteria of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,
132 ve again been recommended by the Sixth Joint National Committee on Prevention, Detection, Evaluation,
133 ideline and under the previous seventh Joint National Committee on Prevention, Detection, Evaluation,
134 according to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,
135 criteria of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,
136 n the basis of the sixth report of the Joint National Committee on Prevention, Detection, Evaluation,
137 e status was "normal" according to the Joint National Committee on Prevention, Detection, Evaluation,
138 erns with recommendations of the Sixth Joint National Committee on Prevention, Detection, Evaluation,
139 uideline and the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation,
140 gh normal" per the sixth report of the Joint National Committee on Prevention, Detection, Evaluation,
141 ry (defined by the sixth report of the Joint National Committee on Prevention, Detection, Evaluation,
142 d-pressure category (as defined by the Joint National Committee on Prevention, Detection, Evaluation,
144 uidelines from the sixth report of the Joint National Committee on Prevention, Detection, Evaluation,
146 and (3) stage of hypertension based on Joint National Committee on Prevention, Detection, Evaluation,
148 sage by larger HMOs and by those with higher National Committee on Quality Assurance (NCQA) ratings.
151 ased link to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluat
152 rtension" in the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluat
155 cal Care Medicine has representatives on the national committees that focus on code creation and defi
156 panel members appointed to the Eighth Joint National Committee titled "2014 Evidence-Based Guideline
157 cording to the established definition (Joint National Committee VII and European Society of Hypertens
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。